Functional status, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio as prognostic factors of one-year survival rate in elderly patients with advanced-stage non-small cell lung cancer

Q3 Medicine

Cancer treatment and research communications Pub Date : 2024-01-01 DOI:10.1016/j.ctarc.2024.100859

Ratna Nurhayati , Aulia Rizka , Cleopas Martin Rumende , Noorwati Sutandyo , Arif Hanafi , Edy Rizal Wahyudi , Hamzah Shatri , Anna Mira Lubis , Em Yunir , Muhammad Firdaus , Yuniar Harris Prayitno , Nadira Nibras Taqiyya

{"title":"Functional status, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio as prognostic factors of one-year survival rate in elderly patients with advanced-stage non-small cell lung cancer","authors":"Ratna Nurhayati , Aulia Rizka , Cleopas Martin Rumende , Noorwati Sutandyo , Arif Hanafi , Edy Rizal Wahyudi , Hamzah Shatri , Anna Mira Lubis , Em Yunir , Muhammad Firdaus , Yuniar Harris Prayitno , Nadira Nibras Taqiyya","doi":"10.1016/j.ctarc.2024.100859","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><div>Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. Aging and chronic inflammation are related to its pathogenesis. Functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio describe a chronic inflammation and correlate to the survival of older adults with advanced-stage (IIIB-IV) NSCLC. This study aims to determine functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio as prognostic factors to 1-year survival in elderly patients with NSCLC stage IIIB-IV.</div></div><div><h3>Methods</h3><div>Survival analysis with a cohort retrospective study is conducted on elderly patients with NSCLC stage IIIB-IV in Dharmais National Cancer Center Hospital between January 2020 and June 2022. Medical records were collected, comprising complete blood count prior to chemotherapy or radiotherapy, assessment of functional status through the Barthel Index for Activities of Daily Living (ADL), and 1-year survival post-diagnosis. Factors potentially influencing outcomes included diabetes mellitus, anemia, chronic obstructive pulmonary disease, and chronic kidney disease. Statistical analyses were performed using SPSS 20.0, employing the log-rank method for bivariate analysis and Cox regression for multivariate analysis.</div></div><div><h3>Results</h3><div>In a cohort of 108 patients, the majority were aged 60–69 years (74.1 %), male (66.7 %), diagnosed at stage IV (80.5 %), and with adenocarcinoma subtype (75.0 %). Significant correlations were observed between the lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio with the 1-year survival rate in elderly patients with stage IIIB-IV NSCLC (<em>p</em> = 0.015 and <em>p</em> = 0.001, respectively). Functional status did not show a significant correlation with 1-year survival overall (<em>p</em> = 0.540), but significant correlations were noted in patients receiving chemotherapy (<em>p</em> = 0.044) and radiotherapy (<em>p</em> = 0.009).</div></div><div><h3>Conclusion</h3><div>The lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio provide significant prognostic insights regarding 1-year survival in elderly patients diagnosed with stage IIIB-IV non-small cell lung cancer (NSCLC). In contrast, the functional status of these patients does not demonstrate a significant correlation with one-year survival.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100859"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294224000716","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aim

Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. Aging and chronic inflammation are related to its pathogenesis. Functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio describe a chronic inflammation and correlate to the survival of older adults with advanced-stage (IIIB-IV) NSCLC. This study aims to determine functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio as prognostic factors to 1-year survival in elderly patients with NSCLC stage IIIB-IV.

Methods

Survival analysis with a cohort retrospective study is conducted on elderly patients with NSCLC stage IIIB-IV in Dharmais National Cancer Center Hospital between January 2020 and June 2022. Medical records were collected, comprising complete blood count prior to chemotherapy or radiotherapy, assessment of functional status through the Barthel Index for Activities of Daily Living (ADL), and 1-year survival post-diagnosis. Factors potentially influencing outcomes included diabetes mellitus, anemia, chronic obstructive pulmonary disease, and chronic kidney disease. Statistical analyses were performed using SPSS 20.0, employing the log-rank method for bivariate analysis and Cox regression for multivariate analysis.

Results

In a cohort of 108 patients, the majority were aged 60–69 years (74.1 %), male (66.7 %), diagnosed at stage IV (80.5 %), and with adenocarcinoma subtype (75.0 %). Significant correlations were observed between the lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio with the 1-year survival rate in elderly patients with stage IIIB-IV NSCLC (p = 0.015 and p = 0.001, respectively). Functional status did not show a significant correlation with 1-year survival overall (p = 0.540), but significant correlations were noted in patients receiving chemotherapy (p = 0.044) and radiotherapy (p = 0.009).

Conclusion

The lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio provide significant prognostic insights regarding 1-year survival in elderly patients diagnosed with stage IIIB-IV non-small cell lung cancer (NSCLC). In contrast, the functional status of these patients does not demonstrate a significant correlation with one-year survival.

查看原文本刊更多论文

功能状态、淋巴细胞/单核细胞比值、血小板/淋巴细胞比值对老年晚期非小细胞肺癌患者1年生存率的影响

背景与目的：非小细胞肺癌（NSCLC）是老年患者中最常见的肺癌。衰老、慢性炎症与其发病机制有关。功能状态、淋巴细胞/单核细胞比率和血小板/淋巴细胞比率描述慢性炎症，并与老年晚期（IIIB-IV）非小细胞肺癌的生存率相关。本研究旨在确定功能状态、淋巴细胞/单核细胞比率和血小板/淋巴细胞比率作为老年NSCLC IIIB-IV期患者1年生存率的预后因素。方法：对2020年1月至2022年6月在达摩国立肿瘤中心医院住院的老年非小细胞肺癌iib - iv期患者进行生存分析，采用队列回顾性研究。收集医疗记录，包括化疗或放疗前的全血细胞计数，通过Barthel日常生活活动指数（ADL）评估功能状态，以及诊断后1年生存率。潜在影响结果的因素包括糖尿病、贫血、慢性阻塞性肺疾病和慢性肾病。采用SPSS 20.0进行统计分析，双变量分析采用log-rank法，多变量分析采用Cox回归。结果：在108例患者队列中，大多数患者年龄在60-69岁（74.1%），男性（66.7%），诊断为IV期（80.5%），腺癌亚型（75.0%）。老年IIIB-IV期NSCLC患者1年生存率与淋巴细胞/单核细胞比值、血小板/淋巴细胞比值有显著相关性（p = 0.015、p = 0.001）。功能状态与1年总体生存率无显著相关性（p = 0.540），但在接受化疗（p = 0.044）和放疗（p = 0.009）的患者中存在显著相关性。结论：淋巴细胞/单核细胞比率和血小板/淋巴细胞比率对诊断为IIIB-IV期非小细胞肺癌（NSCLC）的老年患者的1年生存率提供了重要的预后见解。相反，这些患者的功能状态与1年生存率没有显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.